AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21252018 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI) with sirolimus-eluting stents (SES)
Number of subjects: 1812
Study 21252018 — intervention group
Group type: COMPARATOR
Intervention: Percutaneous coronary intervention (PCI) with bare metal stents (BMS)
Number of subjects: 1812
Study 21252018 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes
Number of subjects: 1812
Study 18214425 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP (with PEEP 10 cmH2O)
Number of subjects: 36
Study 18214425 — intervention group
Group type: EXPERIMENTAL
Intervention: PAV (with PEEP 5‐6 cmH2O)
Number of subjects: 36
Study 18214425 — intervention group
Group type: COMPARATOR
Intervention: CPAP
Number of subjects: 36
Study 18214425 — intervention group
Group type: COMPARATOR
Intervention: PAV
Number of subjects: 36
Study 16611273 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab 5 mg/kg maintenance every 8 weeks
Number of subjects: 282
Study 16611273 — intervention group
Group type: COMPARATOR
Intervention: Placebo maintenance
Number of subjects: 282
Study 12848836 — intervention group
Group type: EXPERIMENTAL
Intervention: Cancer prevention intervention
Number of subjects: 0
Study 12848836 — intervention group
Group type: EXPERIMENTAL
Intervention: Smaller churches
Number of subjects: 0
Study 12848836 — intervention group
Group type: EXPERIMENTAL
Intervention: Churches without recent health activities
Number of subjects: 0
Study 12848836 — intervention group
Group type: EXPERIMENTAL
Intervention: Pastors with less educational attainment
Number of subjects: 0
Study 12848836 — intervention group
Group type: EXPERIMENTAL
Intervention: Pastors making personal lifestyle changes
Number of subjects: 0
Study 11194088 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 0
Study 11194088 — intervention group
Group type: COMPARATOR
Intervention: Raloxifene
Number of subjects: 0
Study 8869676 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmolol infusion (mean rate 330 +/- 10 micrograms/kg/min)
Number of subjects: 20
Study 8869676 — intervention group
Group type: COMPARATOR
Intervention: Routine anesthesia (control group)
Number of subjects: 20
Study 1531487 — intervention group
Group type: EXPERIMENTAL
Intervention: All therapies (including manual therapy, physiotherapy, GP treatment, and placebo)
Number of subjects: 256
Study 6845352 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol 160 mg (divided doses)
Number of subjects: 12
Study 6845352 — intervention group
Group type: COMPARATOR
Intervention: Ethanol (50 ml/70 kg body weight)
Number of subjects: 12
Study 6845352 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol alone
Number of subjects: 12
Study 6845352 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined propranolol and ethanol
Number of subjects: 12
Study 31810456 — intervention group
Group type: EXPERIMENTAL
Intervention: Free paracetamol distribution (experimental arm)
Number of subjects: 117
Study 31810456 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control arm)
Number of subjects: 117
Study 30217233 — intervention group
Group type: EXPERIMENTAL
Intervention: SMART Work & Life intervention with height-adjustable desk (group 1)
Number of subjects: 660
Study 30217233 — intervention group
Group type: EXPERIMENTAL
Intervention: SMART Work & Life intervention without height-adjustable desk (group 2)
Number of subjects: 660
Study 30217233 — intervention group
Group type: COMPARATOR
Intervention: Control group (group 3)
Number of subjects: 660
Study 30217233 — intervention group
Group type: EXPERIMENTAL
Intervention: SMART Work & Life intervention (with or without desk)
Number of subjects: 660
Study 27442691 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard treatment plus contingency management (STCM)
Number of subjects: 65
Study 27442691 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment alone (STA)
Number of subjects: 65
Study 25196301 — intervention group
Group type: EXPERIMENTAL
Intervention: Synbiotic bread (Lactobacillus sporogenes 1 × 10(8) CFU, 0.07 g inulin per 1 g)
Number of subjects: 81
Study 25196301 — intervention group
Group type: EXPERIMENTAL
Intervention: Synbiotic bread
Number of subjects: 81
Study 25196301 — intervention group
Group type: COMPARATOR
Intervention: Probiotic bread
Number of subjects: 81
Study 25196301 — intervention group
Group type: COMPARATOR
Intervention: Control bread
Number of subjects: 81
Study 22615088 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication reconciliation phone call from a medical resident within 72 hours after discharge
Number of subjects: 0
Study 22615088 — intervention group
Group type: COMPARATOR
Intervention: Control group (no phone call)
Number of subjects: 0
Study 20671557 — intervention group
Group type: EXPERIMENTAL
Intervention: 53.2 +/- 0.8% xenon
Number of subjects: 40
Study 20671557 — intervention group
Group type: COMPARATOR
Intervention: 1.6 +/- 0.1% sevoflurane
Number of subjects: 40
Study 18297983 — intervention group
Group type: EXPERIMENTAL
Intervention: Family presence during CPR
Number of subjects: 0
Study 18297983 — intervention group
Group type: EXPERIMENTAL
Intervention: Health care workers' acceptance of family presence
Number of subjects: 0
Study 15885334 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine with adrenaline soaked swabs
Number of subjects: 0
Study 15885334 — intervention group
Group type: COMPARATOR
Intervention: Saline-soaked swabs (Control)
Number of subjects: 0
Study 12011970 — intervention group
Group type: EXPERIMENTAL
Intervention: HR (Paroven, Venoruton; 0‐(beta‐hydroxyethyl)‐rutosides), 1g sachets, twice daily, for 4 weeks
Number of subjects: 40
Study 12011970 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 10466952 — intervention group
Group type: EXPERIMENTAL
Intervention: Processed CPB blood using Continuous AutoTransfusion System (CATS)
Number of subjects: 20
Study 10466952 — intervention group
Group type: COMPARATOR
Intervention: Unprocessed CPB blood (control group)
Number of subjects: 20
Study 8579351 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender-stereotyped health interview
Number of subjects: 38
Study 8579351 — intervention group
Group type: COMPARATOR
Intervention: Nonstereotyped health interview
Number of subjects: 38
Study 2319479 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine 100 mg
Number of subjects: 7
Study 2319479 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine 56 mg
Number of subjects: 7
Study 2319479 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine 18 mg
Number of subjects: 7
Study 2319479 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine 10 mg
Number of subjects: 7
Study 2319479 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 377152 — intervention group
Group type: EXPERIMENTAL
Intervention: 2g metronidazole rectal suppositories
Number of subjects: 200
Study 377152 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 31787562 — intervention group
Group type: EXPERIMENTAL
Intervention: ω‐3 PUFAs (2 g twice daily)
Number of subjects: 4
Study 31787562 — intervention group
Group type: EXPERIMENTAL
Intervention: ω‐3 PUFAs + NX (220 mg twice daily)
Number of subjects: 4
Study 31787562 — intervention group
Group type: EXPERIMENTAL
Intervention: NX (220 mg twice daily)
Number of subjects: 4
Study 31787562 — intervention group
Group type: COMPARATOR
Intervention: Standard nutrition counseling (control)
Number of subjects: 4
Study 27918780 — intervention group
Group type: EXPERIMENTAL
Intervention: Proposed trastuzumab biosimilar
Number of subjects: 500
Study 27918780 — intervention group
Group type: COMPARATOR
Intervention: Trastuzumab
Number of subjects: 500
Study 26310131 — intervention group
Group type: EXPERIMENTAL
Intervention: Gluten-containing flour
Number of subjects: 35
Study 26310131 — intervention group
Group type: COMPARATOR
Intervention: Gluten-free flour
Number of subjects: 35
Study 26310131 — intervention group
Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 35
Study 23294622 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (group P, N=46)
Number of subjects: 88
Study 23294622 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane (group S, N=42)
Number of subjects: 88
Study 21068692 — intervention group
Group type: EXPERIMENTAL
Intervention: Hib-MenC-TT vaccine
Number of subjects: 433
Study 21068692 — intervention group
Group type: COMPARATOR
Intervention: Separate Hib-TT and MenC-CRM197 vaccines
Number of subjects: 433
Study 19228863 — intervention group
Group type: EXPERIMENTAL
Intervention: Pedometers and text messaging
Number of subjects: 78
Study 19228863 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 78
Study 16881424 — intervention group
Group type: EXPERIMENTAL
Intervention: Missile trocar
Number of subjects: 100
Study 16881424 — intervention group
Group type: COMPARATOR
Intervention: Veress needle
Number of subjects: 100
Study 15006828 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil (50 mg)
Number of subjects: 35
Study 11704315 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg/m(2) amifostine i.v. 30 min before radiation
Number of subjects: 73
Study 11704315 — intervention group
Group type: COMPARATOR
Intervention: Control (no amifostine)
Number of subjects: 73
Study 9033316 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin-coated cardiopulmonary bypass circuit
Number of subjects: 30
Study 9033316 — intervention group
Group type: COMPARATOR
Intervention: Uncoated cardiopulmonary bypass circuit
Number of subjects: 30
Study 8345794 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral therapy (conjugated equine estrogens, 0.625 mg/d continuous + levonorgestrel, 0.075 mg/d for 12 days of each 28‐day cycle)
Number of subjects: 61
Study 8345794 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal therapy (estradiol 17 beta, 0.05 mg/d continuous + norethindrone acetate, 0.25 mg/d for 14 days of each 28‐day cycle)
Number of subjects: 61
Study 8345794 — intervention group
Group type: COMPARATOR
Intervention: Untreated control group (30 postmenopausal women not seeking HRT)
Number of subjects: 61
Study 3733414 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasmapheresis (PP)
Number of subjects: 5
Study 3733414 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated by PP)
Number of subjects: 5
Study 31961284 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple Family Group (MFG) intervention
Number of subjects: 19
Study 31961284 — intervention group
Group type: COMPARATOR
Intervention: Education Control Group (EC)
Number of subjects: 19
Study 29807958 — intervention group
Group type: EXPERIMENTAL
Intervention: Group III (laser)
Number of subjects: 45
Study 29807958 — intervention group
Group type: EXPERIMENTAL
Intervention: Group II (magic foam)
Number of subjects: 45
Study 29807958 — intervention group
Group type: EXPERIMENTAL
Intervention: Group I (retraction cord impregnated with aluminum chloride)
Number of subjects: 45
Study 27855699 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged Exposure Treatment for Adolescents (PE-A)
Number of subjects: 11
Study 27855699 — intervention group
Group type: COMPARATOR
Intervention: Supportive Counselling (SC)
Number of subjects: 11
Study 24132138 — intervention group
Group type: EXPERIMENTAL
Intervention: Stretching Training (ST)
Number of subjects: 28
Study 24132138 — intervention group
Group type: COMPARATOR
Intervention: No-exercise control (CON)
Number of subjects: 28
Study 25885496 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal saline 4 mL/kg (group L)
Number of subjects: 80
Study 25885496 — intervention group
Group type: COMPARATOR
Intervention: Normal saline 10 mL/kg (group H)
Number of subjects: 80
Study 20685760 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive resistance training (PRT), biweekly for 12 weeks, starting from 15RM to 8RM
Number of subjects: 38
Study 20685760 — intervention group
Group type: COMPARATOR
Intervention: Control group maintained usual daily activity level
Number of subjects: 38
Study 19071987 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally specific (CS) smoking cessation guide
Number of subjects: 182
Study 19071987 — intervention group
Group type: COMPARATOR
Intervention: Standard smoking cessation guide
Number of subjects: 182
Study 15673385 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 55
Study 15673385 — intervention group
Group type: COMPARATOR
Intervention: No antiarrhythmic drug therapy
Number of subjects: 55
Study 12377641 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel/carboplatin
Number of subjects: 618
Study 12377641 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel/cisplatin
Number of subjects: 618
Study 10530408 — intervention group
Group type: EXPERIMENTAL
Intervention: Ig heavy chain (IgH) gene rearrangements using primers directed to framework regions (FR) 1, 2 and 3
Number of subjects: 91
Study 10530408 — intervention group
Group type: EXPERIMENTAL
Intervention: T-cell receptor (TCR) gene rearrangements using primers hybridising to TCR delta and gamma genes
Number of subjects: 91
Study 10530408 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of all five primer sets
Number of subjects: 91
Study 10530408 — intervention group
Group type: EXPERIMENTAL
Intervention: Analysis of oligoclonal patterns
Number of subjects: 91
Study 10530408 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparative analysis of samples from different compartments
Number of subjects: 91
Study 10530408 — intervention group
Group type: EXPERIMENTAL
Intervention: Detection of large size PCR products (540-715 bp)
Number of subjects: 91
Study 10530408 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimum of three targets for detection
Number of subjects: 91
Study 8750162 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon treatment
Number of subjects: 26
Study 8750162 — intervention group
Group type: COMPARATOR
Intervention: Control group (not treated with interferon)
Number of subjects: 26
Study 2074246 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefodizime
Number of subjects: 3791
Study 2074246 — intervention group
Group type: COMPARATOR
Intervention: Cefotaxime or Cefuroxime
Number of subjects: 3791
Study 6781589 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical examination
Number of subjects: 0
Study 6781589 — intervention group
Group type: EXPERIMENTAL
Intervention: Tubigrip support
Number of subjects: 0
Study 6781589 — intervention group
Group type: COMPARATOR
Intervention: X-ray examination
Number of subjects: 0
Study 6092555 — intervention group
Group type: EXPERIMENTAL
Intervention: CAV plus thoracic irradiation (4,000 rad TD, split course)
Number of subjects: 291
Study 6092555 — intervention group
Group type: COMPARATOR
Intervention: CAV without thoracic irradiation
Number of subjects: 291
Study 6092555 — intervention group
Group type: EXPERIMENTAL
Intervention: CAV plus brain irradiation
Number of subjects: 291
Study 6092555 — intervention group
Group type: EXPERIMENTAL
Intervention: CAV plus brain irradiation plus thoracic irradiation
Number of subjects: 291
Study 6092555 — intervention group
Group type: EXPERIMENTAL
Intervention: CAV plus thoracic irradiation
Number of subjects: 291
Study 6092555 — intervention group
Group type: COMPARATOR
Intervention: CAV and brain irradiation without thoracic radiotherapy
Number of subjects: 291
Study 29920211 — intervention group
Group type: EXPERIMENTAL
Intervention: Blended dairy (3 servings/day for 4 weeks)
Number of subjects: 16
Study 29920211 — intervention group
Group type: COMPARATOR
Intervention: Control group (rs6720173‐GG, rs3808607‐G, and rs760241‐A genotypes)
Number of subjects: 16
Study 27294502 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus casei Shirota probiotic (PRO)
Number of subjects: 243
Study 27294502 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 243
Study 24401211 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 PUFAs (2 g/day for 12 weeks)
Number of subjects: 29
Study 24401211 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 24401211 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 PUFAs
Number of subjects: 29
Study 22206609 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-tube voltage (80 kVp) 320-detector row volume CT angiography (L-VCTA)
Number of subjects: 48
Study 22206609 — intervention group
Group type: COMPARATOR
Intervention: Conventional-tube voltage (120 kVp) volume CT angiography (C-VCTA)
Number of subjects: 48
Study 20435965 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-based intervention (12-week programme plus three booster sessions)
Number of subjects: 84
Study 20435965 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 84
Study 17934183 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 150
Study 17934183 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study 15858300 — intervention group
Group type: EXPERIMENTAL
Intervention: Mineral trioxide aggregate (MTA) as a pulpotomy medicament
Number of subjects: 0
Study 11811169 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. CRF as a 1.0-microg/kg bolus followed by a constant infusion (1.0 microg/kg/h)
Number of subjects: 6
Study 11811169 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 6
Study 10423023 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery for peptic ulcer disease
Number of subjects: 438
Study 10423023 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroids
Number of subjects: 438
Study 10423023 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyroid replacement
Number of subjects: 438
Study 10423023 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic anticoagulation
Number of subjects: 438
Study 10423023 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastrectomy with Billroth II reconstruction
Number of subjects: 438
Study 10423023 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher body mass index
Number of subjects: 438
Study 10423023 — intervention group
Group type: EXPERIMENTAL
Intervention: Female gender
Number of subjects: 438
Study 7554762 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute hypoxia at 3440 m
Number of subjects: 24
Study 7554762 — intervention group
Group type: COMPARATOR
Intervention: Subjects with symptoms of acute mountain sickness at 4120 or 5200 m
Number of subjects: 24
Study 7554762 — intervention group
Group type: EXPERIMENTAL
Intervention: Raised intracranial pressure
Number of subjects: 24
Study 2405994 — intervention group
Group type: EXPERIMENTAL
Intervention: Transurethral debulking surgery combined with upfront CMV chemotherapy plus cisplatin and 4000 cGy
Number of subjects: 0
Study 2405994 — intervention group
Group type: COMPARATOR
Intervention: Neoadjuvant MCV chemotherapy for selective bladder preservation
Number of subjects: 0
Study 6115808 — intervention group
Group type: EXPERIMENTAL
Intervention: LH-RH treatment
Number of subjects: 62
Study 6115808 — intervention group
Group type: COMPARATOR
Intervention: Surgical treatment
Number of subjects: 62
Study 31147359 — intervention group
Group type: EXPERIMENTAL
Intervention: Morita Therapy (MT)
Number of subjects: 16
Study 31147359 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 16
Study 28685888 — intervention group
Group type: EXPERIMENTAL
Intervention: Phase 2 in-person health survey invitation
Number of subjects: 599
Study 28685888 — intervention group
Group type: EXPERIMENTAL
Intervention: Phase 1 household enumeration questionnaire
Number of subjects: 599
Study 27314331 — intervention group
Group type: EXPERIMENTAL
Intervention: Darmocare Pre(®) (prebiotic formulation)
Number of subjects: 60
Study 27314331 — intervention group
Group type: COMPARATOR
Intervention: Placebo (maltodextrin)
Number of subjects: 60
Study 25825102 — intervention group
Group type: EXPERIMENTAL
Intervention: 8% lignocaine gel
Number of subjects: 42
Study 25825102 — intervention group
Group type: COMPARATOR
Intervention: 15% lignocaine spray
Number of subjects: 42
Study 21932114 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly minodronate at 30 mg
Number of subjects: 692
Study 21932114 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly minodronate at 50 mg
Number of subjects: 692
Study 21932114 — intervention group
Group type: COMPARATOR
Intervention: Daily minodronate at 1 mg
Number of subjects: 692
Study 21932114 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (30 mg, 50 mg, and 1 mg daily)
Number of subjects: 692
Study 19188545 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine-based chemotherapy (gemcitabine plus carboplatin, paclitaxel, or cisplatin)
Number of subjects: 85
Study 19188545 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine-based chemotherapy
Number of subjects: 85
Study 18265541 — intervention group
Group type: EXPERIMENTAL
Intervention: Twelve‐week heart health education and physical activity program
Number of subjects: 120
Study 16318830 — intervention group
Group type: EXPERIMENTAL
Intervention: hioxofilcon A
Number of subjects: 40
Study 16318830 — intervention group
Group type: EXPERIMENTAL
Intervention: omafilcon A
Number of subjects: 40
Study 11725940 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily records of physical activity (intervention group)
Number of subjects: 49
Study 11725940 — intervention group
Group type: COMPARATOR
Intervention: No records (control group)
Number of subjects: 49
Study 9164824 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg Ca as AAACa after each meal and 450 mg at bedtime
Number of subjects: 9
Study 9164824 — intervention group
Group type: COMPARATOR
Intervention: 300 mg after each meal
Number of subjects: 9
Study 9164824 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 8232735 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventionally Fractionated Radiotherapy (CFR)
Number of subjects: 49
Study 8232735 — intervention group
Group type: EXPERIMENTAL
Intervention: Large Fractionated Radiotherapy (LFR)
Number of subjects: 49
Study 3111280 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalation of 35% CO2 and 65% O2; Duration: Not specified
Number of subjects: 8
Study 3111280 — intervention group
Group type: COMPARATOR
Intervention: Placebo; Duration: Not specified
Number of subjects: 8
Study 31200662 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical therapy
Number of subjects: 92
Study 31200662 — intervention group
Group type: COMPARATOR
Intervention: Revascularization
Number of subjects: 92
Study 28408411 — intervention group
Group type: EXPERIMENTAL
Intervention: Active Avoidance
Number of subjects: 0
Study 28408411 — intervention group
Group type: COMPARATOR
Intervention: Yoked Extinction
Number of subjects: 0